close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

151.12 -1.62 (-1.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
News headline image
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
From Gilead Sciences, Inc.
Via Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Mount Gilead, NC Author Publishes Children's Book
Take In The Beauty Of Nature And Quiet The Outside World. 
Via PR Leap
News headline image
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
News headline image
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Appoints Cindy Perettie Executive Vice President of Kite
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
From Arcus Biosciences
Via Business Wire
News headline image
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
From Gilead Sciences, Inc.
Via Business Wire
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
Via Investor Brand Network
News headline image
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces First Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
6 Best Healthcare Stocks to Buy Right Now
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat. 
Via MarketBeat
Topics Economy Intellectual Property
News headline image
Gamida Cell Stock Jumps Over 100% on FDA Approval
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo 
Via MarketBeat
News headline image
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
From Gilead Sciences, Inc.
Via Business Wire
Balm of Gilead’s Manuka Honey Skin Healing Cream Named “Best for Healing Skin Conditions” by US Weekly Magazine
Via Get News
News headline image
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
From Gilead Sciences, Inc.
Via Business Wire
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga 
Via TheNewswire.com
News headline image
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
News headline image
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite Completes Acquisition of Tmunity
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today